ReNew Publishes First Annual Integrated Report Aligned With International Integrated Reporting Standards
5.8.2024 16:56:00 EEST | Business Wire | Press release
ReNew Energy Global Plc ("ReNew") (NASDAQ: RNW), India’s leading decarbonization solutions provider, released its first Annual Integrated Report (for FY 2023-24) today. The report titled ‘Innovating Clean Energy Solutions’ reinforces ReNew’s position as a global pioneer in the clean energy landscape while integrating sustainability, nurturing equity, and embodying responsible stewardship.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805395803/en/
From left to right: Vaishali Nigam Sinha, Co-Founder & Chairperson, Sustainability, ReNew; Sir Sumantra Chakrabarti, Chairperson, ESG Committee and Independent Director, ReNew; and Sumant Sinha, Founder, Chairman & CEO, ReNew at ReNew Hub on Friday, 2 August, 2024 (Photo: Business Wire)
The report demonstrates ReNew’s commitment to ensure its disclosures go above and beyond any single geographical reporting standard and to continue to advance towards enhanced global reporting standards. ReNew has, for the first time, aligned with the EU Taxonomy and reports 97.79% of its capital expenditure aligned with it. The taxonomy is a classification system that lays out the criteria for economic activities which are aligned with a net-zero trajectory by 2050. This strategic move bolsters sustainable investment and elevates the transparency of its economic activities, in harmony with climate objectives and broader environmental goals.
Sumant Sinha, Founder, Chairman, and CEO, ReNew, said: “As a pioneer in India’s renewable energy sector, we are committed to strategically expanding our footprint in the Indian market with targeted investments in select emerging markets globally. As we look ahead, we envision doubling our aggregate portfolio to ~21 GW in the next five years. Our first Annual Integrated Report reflects our commitment to scale up renewable energy projects and meet the growing demand for clean and sustainable power solutions in an environmentally and socially responsible manner.”
ReNew also undertook its first Double Materiality Assessment in FY 2023-24, a notable responsibility in its journey towards sustainable excellence. Double materiality is an impact assessment method which shows an organization’s actual and potential adverse impacts on people, society and the environment from both a financial and non-financial perspective.
As outlined in the report, FY 2023-24 was marked by significant milestones for ReNew. The Company crossed the mark of 10 GW set up cumulative capacity and recorded a net profit of INR 4,147 million (US$ 50 million).
Vaishali Nigam Sinha, Co-Founder and Chairperson - Sustainability, ReNew, said:“As the world inches closer to the critical 1.5 degrees Celsius climate threshold, we, at ReNew, are playing a pivotal role in enabling India’s low carbon development pathways. We have committed to net-zero goals by 2040, validated by the Science Based Targets initiative (SBTi), which makes us one of the first pure-play renewable energy companies to receive this recognition.”
Solidifying its position as a leading clean energy player, ReNew reported 16 million tonnes of CO2e mitigation, accounting for ~0.6% of India’s total carbon emissions. Demonstrating tangible progress towards its own net-zero commitment by 2040, the Company witnessed a ~10% reduction in Scope 1 and 2 emissions for FY 2023-24 compared to the baseline year FY 2021-22. ReNew also achieved carbon neutrality for Scope 1 and Scope 2 emissions for the fourth consecutive year. Scope 1 are direct emissions owned or controlled by a company, whereas Scope 2 are indirect emissions from the generation of purchased electricity consumed by a company.
ReNew has reinstated its commitment to building an environment that prioritizes employee safety and inclusivity. The Company was certified a ‘Great Place to Work’ for the fourth consecutive year and recorded an employee gender diversity rate of ~14%, with ~10% women representation in science, technology, engineering, and maths (STEM) roles, far surpassing industry standards.
ReNew’s Annual Integrated Report FY 2023-24 is available here.
Note to Editors:
About the Report:
The Annual Integrated Report FY 2023-24 was crafted in alignment with the International Integrated Reporting Council (IIRC) framework established by the International Financial Reporting Standards (IFRS) Foundation. In preparing this report, ReNew has also referenced the Global Reporting Initiative (GRI) Standards 2021, United Nations Sustainable Development Goals (UN SDGs), Sustainability Accounting Standards Board (SASB), United Nations Global Compact (UNGC), United Nations Women’s Empowerment Principles (UNWEP), International Finance Corporation (IFC) Standards, Equator Principles (EP) and Task Force on Climate-related Financial Disclosures (TCFD). The Double Materiality methodology was based on the European Financial Reporting Advisory Group (EFRAG) under the Corporate Sustainability Reporting Directive (CSRD) and aligns with the requirements of IFRS standards. The non-financial sustainability information presented in the Report is externally assured by Ernst and Young Associates LLP. The financial statements presented in the Report are audited by S.R. Batliboi & Co. LLP, a network firm of Ernst & Young.
About ReNew
ReNew is a leading decarbonization solutions company listed on Nasdaq (NASDAQ: RNW). ReNew's clean energy contracted portfolio of ~15.6 GW as of May 31, 2024, is one of the largest globally. In addition to being a major independent power producer in India, we provide end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. For more information, visit www.renew.com and follow us on LinkedIn, Facebook, Twitter and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805395803/en/
Contacts
Press Enquiries
Shilpa Narani | shilpa.narani@renew.com
Investor Enquiries
Nathan Judge, Anunay Shahi, Nitin Vaid | ir@renew.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom